In an order posted to the site of the U.S. District Court for the District of Delaware, the court stated: “10x Genomics (TXG), Inc. and Prognosys Biosciences, Inc. sued NanoString Technologies, Inc.1 for patent infringement. Following a five-day trial, the jury found that NanoString willfully, directly, and indirectly infringed 10x’s asserted patents. The jury awarded 10x over twenty-five million dollars in lost profits and over six million dollars in lost royalties. NanoString has moved for judgment as a matter of law on invalidity, infringement, and damages or, in the alternative, for a new trial. 10x, on the other hand, has moved for entry of a permanent injunction, enhancement of damages, attorneys’ fees, supplemental damages, and pre-judgment and post-judgment interest… the Court denies NanoString’s motion and grants 10x’s motion in part.” The filing noted: “Bruker (BRKR) Corporation acquired NanoString following the filing of these motions. In this decision, the Court will refer to the defendants as NanoString.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.